84 related articles for article (PubMed ID: 19087519)
1. [Clinical evaluation of autoantibody of splice variant of BARD1 in detection of ovarian cancer].
Yang ZJ; Jiang YM; Yang G; Ran YL; Yang ZH; Zhang W; Zhang JQ; Pan ZM; Li L
Zhonghua Fu Chan Ke Za Zhi; 2008 Sep; 43(9):680-4. PubMed ID: 19087519
[TBL] [Abstract][Full Text] [Related]
2. [Clinical study of autoantibody spectrum against ovarian cancer associated antigens combined with CA(125) in detecting and monitoring ovarian cancer].
Yang ZJ; Yang G; Jiang YM; Ran YL; Yang ZH; Zhang W; Zhang JQ; Pan ZM; Li L
Zhonghua Fu Chan Ke Za Zhi; 2011 Feb; 46(2):113-8. PubMed ID: 21426769
[TBL] [Abstract][Full Text] [Related]
3. BARD1 Autoantibody Blood Test for Early Detection of Ovarian Cancer.
Pilyugin M; Ratajska M; Stukan M; Concin N; Zeillinger R; Irminger-Finger I
Genes (Basel); 2021 Jun; 12(7):. PubMed ID: 34201956
[TBL] [Abstract][Full Text] [Related]
4. [Screening and sero-immunoscreening of ovarian epithelial cancer associative antigens].
Yang ZJ; Yang G; Jiang YM; Ran YL; Yang ZH; Zhang W; Zhang JQ; Pan ZM; Li L
Zhonghua Fu Chan Ke Za Zhi; 2007 Dec; 42(12):834-9. PubMed ID: 18476518
[TBL] [Abstract][Full Text] [Related]
5. BARD1, a possible biomarker for breast and ovarian cancer.
Irminger-Finger I
Gynecol Oncol; 2010 May; 117(2):211-5. PubMed ID: 19959210
[TBL] [Abstract][Full Text] [Related]
6. [The values of serum human epididymis secretory protein 4 and CA(125) assay in the diagnosis of ovarian malignancy].
Dong L; Chang XH; Ye X; Zhu LR; Zhao Y; Tian L; Cheng HY; Li XP; Zhang H; Liao QP; Fu TY; Cheng YX; Cui H
Zhonghua Fu Chan Ke Za Zhi; 2008 Dec; 43(12):931-6. PubMed ID: 19134334
[TBL] [Abstract][Full Text] [Related]
7. Serum autoantibodies against a panel of 15 tumor-associated antigens in the detection of ovarian cancer.
Sun H; Shi JX; Zhang HF; Xing MT; Li P; Dai LP; Luo CL; Wang X; Wang P; Ye H; Li LX; Zhang JY
Tumour Biol; 2017 Jun; 39(6):1010428317699132. PubMed ID: 28618923
[TBL] [Abstract][Full Text] [Related]
8. BARD1 serum autoantibodies for the detection of lung cancer.
Pilyugin M; Descloux P; André PA; Laszlo V; Dome B; Hegedus B; Sardy S; Janes S; Bianco A; Laurent GJ; Irminger-Finger I
PLoS One; 2017; 12(8):e0182356. PubMed ID: 28786985
[TBL] [Abstract][Full Text] [Related]
9. Oncogenic BARD1 isoforms expressed in gynecological cancers.
Li L; Ryser S; Dizin E; Pils D; Krainer M; Jefford CE; Bertoni F; Zeillinger R; Irminger-Finger I
Cancer Res; 2007 Dec; 67(24):11876-85. PubMed ID: 18089818
[TBL] [Abstract][Full Text] [Related]
10. p53 autoantibodies as potential detection and prognostic biomarkers in serous ovarian cancer.
Anderson KS; Wong J; Vitonis A; Crum CP; Sluss PM; Labaer J; Cramer D
Cancer Epidemiol Biomarkers Prev; 2010 Mar; 19(3):859-68. PubMed ID: 20200435
[TBL] [Abstract][Full Text] [Related]
11. Identification and characterization of missense alterations in the BRCA1 associated RING domain (BARD1) gene in breast and ovarian cancer.
Sauer MK; Andrulis IL
J Med Genet; 2005 Aug; 42(8):633-8. PubMed ID: 16061562
[TBL] [Abstract][Full Text] [Related]
12. Autoantibody biomarkers identified by proteomics methods distinguish ovarian cancer from non-ovarian cancer with various CA-125 levels.
Karabudak AA; Hafner J; Shetty V; Chen S; Secord AA; Morse MA; Philip R
J Cancer Res Clin Oncol; 2013 Oct; 139(10):1757-70. PubMed ID: 23999876
[TBL] [Abstract][Full Text] [Related]
13. Autoantibody biomarker opens a new gateway for cancer diagnosis.
Nesterova M; Johnson N; Cheadle C; Cho-Chung YS
Biochim Biophys Acta; 2006 Apr; 1762(4):398-403. PubMed ID: 16483750
[TBL] [Abstract][Full Text] [Related]
14. Aberrant expression of BARD1 in breast and ovarian cancers with poor prognosis.
Wu JY; Vlastos AT; Pelte MF; Caligo MA; Bianco A; Krause KH; Laurent GJ; Irminger-Finger I
Int J Cancer; 2006 Mar; 118(5):1215-26. PubMed ID: 16152612
[TBL] [Abstract][Full Text] [Related]
15. Circulating IL-8 and anti-IL-8 autoantibody in patients with ovarian cancer.
Lokshin AE; Winans M; Landsittel D; Marrangoni AM; Velikokhatnaya L; Modugno F; Nolen BM; Gorelik E
Gynecol Oncol; 2006 Aug; 102(2):244-51. PubMed ID: 16434085
[TBL] [Abstract][Full Text] [Related]
16. RNA assay identifies a previous misclassification of BARD1 c.1977A>G variant.
Rofes P; Pineda M; Feliubadaló L; Menéndez M; de Cid R; Gómez C; Montes E; Capellá G; Brunet J; Del Valle J; Lázaro C
Sci Rep; 2021 Nov; 11(1):22948. PubMed ID: 34824355
[TBL] [Abstract][Full Text] [Related]
17. Afamin and apolipoprotein A-IV: novel protein markers for ovarian cancer.
Dieplinger H; Ankerst DP; Burges A; Lenhard M; Lingenhel A; Fineder L; Buchner H; Stieber P
Cancer Epidemiol Biomarkers Prev; 2009 Apr; 18(4):1127-33. PubMed ID: 19336561
[TBL] [Abstract][Full Text] [Related]
18. Use of a combination of approaches to identify and validate relevant tumor-associated antigens and their corresponding autoantibodies in ovarian cancer patients.
Gagnon A; Kim JH; Schorge JO; Ye B; Liu B; Hasselblatt K; Welch WR; Bandera CA; Mok SC
Clin Cancer Res; 2008 Feb; 14(3):764-71. PubMed ID: 18245537
[TBL] [Abstract][Full Text] [Related]
19. The "reverse capture" autoantibody microarray : an innovative approach to profiling the autoantibody response to tissue-derived native antigens.
Ehrlich JR; Tang L; Caiazzo RJ; Cramer DW; Ng SK; Ng SW; Liu BC
Methods Mol Biol; 2008; 441():175-92. PubMed ID: 18370319
[TBL] [Abstract][Full Text] [Related]
20. Identification of epithelial cell adhesion molecule autoantibody in patients with ovarian cancer.
Kim JH; Herlyn D; Wong KK; Park DC; Schorge JO; Lu KH; Skates SJ; Cramer DW; Berkowitz RS; Mok SC
Clin Cancer Res; 2003 Oct; 9(13):4782-91. PubMed ID: 14581349
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
